Shares of Regeneron and Sanofi are opening the week higher after researchers revealed Sunday an experimental cholesterol-lowering drug nearly halved the number of heart attacks and strokes in a clinical trial. While the result is not conclusive, the analysis does offer preliminary evidence that targeting a protein known as PCSK9 could reduce cardiovascular risks for millions. The injectable drug - Alirocumab - is from a new class of medicines also being developed by Amgen and Pfizer. This new class of drug lowers "bad" LDL cholesterol and is said to have multibillion-dollar sales potential. TheStreet's Gregg Greenberg has details from New York.